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ABSTRACT: A novel and mild Rh(III)-catalyzed [5+2] oxidative annulation between cyclic arylguanidines and alkynes efficiently affords 
1,3-benzodiazepines (pentacyclic guanidines). The use of O2 as the sole oxidant in place commonly used metal oxidants such as AgOAc 
clearly improves the efficiency of the oxidative annulation process. The mechanism of the cycloaddition most likely involves the formation of 
an eight-membered rhodacycle. DFT calculations support a striking mechanistic proposal for the [5+2] oxidative annulation. 
Benzodiazepines are an important class of benzofused medium-
sized dinitrogenated heterocycles,1 and they are the key structural 
motifs in many active pharmaceuticals.2 These compounds com-
prise several structural derivatives but the most interesting are the 
1,4-benzodiazepines, which have attracted significant synthetic 
effort due to their broad range of clinical applications in the treat-
ment of anxiety, insomnia, agitation, seizures or muscle spasms.3 
Other structural isomers, such as 1,3-benzodiazepines, are less well 
known despite the fact that these molecules have a wide range of 
medicinal applications4 (Figure 1). Accordingly, sustainable cata-
lytic routes for the construction of the 1,3-benzodiazepine core are 
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Figure 1. Bioactive 1,3-benzodiazepines. 
Transition-metal-catalyzed C_H functionalization is nowadays 
considered to be a powerful synthetic sustainable strategy for a 
direct access to five- and six-membered azaheterocycles.6 Typically, 
the process of heteroannulation of nitrogen-chelating substrates 
with alkynes involves the formation of six- and seven-membered 
metallacycles through a C_H activation/alkyne insertion sequence 
that gives rise to the corresponding azaheterocycles via reductive 
elimination, which overall can be considered as formal [3+2] or 
[4+2] oxidative annulations.6 However, the formation of eight-
membered metallacycle intermediates is energetically more unfa-
vorable and this has undoubtedly restricted the direct access to 
seven-membered azaheterocycles. To the best of our knowledge, 
only two reports on the direct Pd-catalyzed [5+2] cycloaddition 
between nitrogen-containing preorganized substrates and alkynes 
to form 1-benzazepine derivatives have been published.7 On the 
other hand, we recently discovered that 1,3-dimethyl-1,3-
diphenylguanidine 1a (i.e., linear arylguanidines) easily undergo 
catalytic C-H activation/alkyne insertion processes to form the 
eight-membered rhodacycle 3, which could be isolated and charac-
terized by X-ray diffraction.8 In a catalytic process involving 3-
hexyne 2a, the corresponding metallacyclic intermediate 3 evolved 
via β-elimination to 1,4-dihydroquinazolin-2-amine 4aa, which is 
the product of a [5+1] oxidative annulation between the linear 
arylguanidine and the alkyne (Scheme 1, eq 1).8 We envisaged that 
the use of partially and/or fully cyclic arylguanidines 1 would modi-
fy the conformational/coordination abilities of rhodacycle inter-
 
mediates 3 to favor the crucial reductive elimination step to give 
the desired seven-membered heterocycle. Herein we report the 
straightforward formation of the seven-membered benzimidazo-
1,3-benzodiazepines 5 by a novel Rh(III)-catalyzed [5+2] oxidative 
annulation of fully cyclic arylguanidines 1 with alkynes 2 (Scheme 
1, eq 2).9 It is noteworthy that in the C-H activation event two 
nitrogen atoms of the chelate-directing guanidine group were 
integrated in the final 1,3-benzodiazepine core. 
Scheme 1. Rh(III)-catalyzed [5+1] and [5+2] oxidative annula-
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[5+2] oxidative annulation
 
The partially cyclic N-methyl-N-phenyl-1H-benzo[d]imidazol-
2-amine 1b reacted sluggishly to give 4ba in a low 18% yield 
(Scheme 2, eq 1), with most of the 1b recovered.10 Gratifyingly, 
when the fully cyclic 2-(indolin-1-yl)-1H-benzo[d]imidazole 1c 
was heated in MeOH at 80°C (conditions A), a smooth conversion 
gave the benzimidazo-1,3-benzodiazepine 5ca in a respectable 60% 
yield (Scheme 2, eq 2). To our delight, the yield of the reaction 
could be improved to 85% when O2 was used as the sole oxidant 
(conditions B).11 
Scheme 2. Rh(III)-catalyzed oxidative annulations of partially 
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We proceeded to test the scope and limitations of the new [5+2] 
annulation using cyclic arylguanidine 1c as the substrate under 
both sets of oxidative conditions.12 In general, reactions performed 
using O2 as the sole oxidant (conditions B) gave better yields 
(Table 1). Thus, other internal aliphatic alkynes, namely 4-octyne 
2b and 5-decyne 2c, gave the corresponding 1,3-benzodiazepines 
5cb-cc in high yields (entries 2 and 3). Interestingly, unlike the 
cycloaddition with linear arylguanidines,8 aromatic alkynes 2d-k 
reacted smoothly to give the corresponding 4,5-diarylated 1,3-
benzodiazepines 5cd-ck. In the case of diphenylacetylene 2d, 
excellent yields of 1,3-benzodiazepine 5cd were obtained under 
both sets of conditions (entry 4). The molecular structure of 5cd 
was elucidated by X-ray crystallography.13 Electron-rich and 
electron-poor arylalkynes were all tolerated, with insignificant 
variations in the cycloadditions. Thus, 4-methoxy, 4-methyl and 4-
trifluoromethyl arylalkynes 2e-g gave rise to 1,3-benzodiazepines 
5ce-cg in very good yields (entries 5-7). The case of 
heteroarylalkyne 2h was particulary efficient and this gave rise to 
the thiophenyl derivative 5ch in high yield (entry 8). Halogenated 
arylalkynes were also well tolerated, which may lead to future cross-
coupling manipulations. For example, 4-Br, 4-Cl and 3-Br 
arylalkyne derivatives 2i-k gave moderate to good yields of the 
corresponding halogenated 1,3-benzodiazepines 5ci-ck (entries 9-
11). Curiously, the [5+2] cycloaddition proved to be non 
regioselective – in contrast to the regioselective [5+1] 
cycloaddition with linear arylguanidines.8 Thus, the alkyne 1-
(propynyl)benzene 2l, bearing Csp2 and Csp3 substituents, gave rise 
to a mixture of regioisomers 5cl and 5cl’ (1.5:1) in a 75% 
combined yield (entry 12). 
Table 1. Rh(III)-catalyzed [5+2] oxidative annulation of cyclic 
arylguanidine 1c with alkynes 2 to 1,3-benzodiazepines 5 
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5 5cd X-Ray  
entry R1 R2 product yield (%)a,b 
1 Et Et 5ca 60 (85) 
2 n-Pr n-Pr 5cb 51 (82) 
3 n-Bu n-Bu 5cc 47 (81) 
4 Ph Ph 5cd 88 (93) 
5 4-MeOPh 4-MeOPh 5ce 70 
6 4-MePh 4-MePh 5cf 57 (84) 
7 4-CF3Ph 4-CF3Ph 5cg 52 (81) 
8 2-thiophenyl 2-thiophenyl 5ch 82 (82) 
9 4-BrPh 4-BrPh 5ci 51 
10 4-ClPh 4-ClPh 5cj 43 
11 3-BrPh 3-BrPh 5ck 36 (87) 




a Conditions A: 1c (0.3 mmol), 2 (0.33 mmol), [RhCp*Cl2]2 
(0.0075 mmol), AgOAc (0.63 mmol) in MeOH (3 mL), 80 °C, air, 
24h. Conditions B: 1c (0.3 mmol), 2 (0.33 mmol), [RhCp*Cl2]2 
(0.0075 mmol), in MeOH (3 mL), O2, 80 °C, 24h. b In parenthesis, 
yields obtained under conditions B. 
 
Other cyclic arylguanidines were also tested (Figure 2). The 
substituted 2-(methylindolyl)guanidine 1d also reacted smoothly 
to give the 1,3-benzodiazepine 5dd in good yield (80%). Both 
electron-rich and electron-poor para-substituted indolyl units were 
well tolerated since indolyl guanidines 1e and 1f gave the 1,3-
benzodiazepines 5ed and 5fd in excellent yields.14 Gratifyingly, the 
2-(indol-1-yl)-1,3-benzimidazole derivative 1i also underwent the 
[5+2] oxidative annulation15 to give the indolo-1,3-benzodiazepine 

























1d R1 = Me; R2
 =H
1e R1= H; R2 = OMe
1f R1= H; R2
 = Br
1g n = 2
1h n = 3
1i 1j




a Conditions A: 1 (0.3 mmol), 2 (0.33 mmol), [RhCp*Cl2]2 (0.0075 
mmol), AgOAc (0.63 mmol) in MeOH (3 mL), 80 ºC, air, 24h. Condi-
tions B: 1 (0.3 mmol), 2 (0.33 mmol), [RhCp*Cl2]2 (0.0075 mmol), in 
MeOH (3 mL), O2, 80 ºC, 24h. b In parenthesis, yields obtained under 
conditions B. 
Figure 2. Rh(III)-catalyzed oxidative annulations of other cyclic aryl-
guanidines.a,b 
The starting indole 1i could be prepared in moderate yields from 
the readily available 2-(N-phenyl)-1,3-benzimidazole 1k in a 
Rh(III)-catalyzed [3+2] oxidative cycloaddition with 3-hexyne 
(Scheme 3).8,16 To our delight, the above indolo-1,3-
benzodiazepine 5ia (which was characterized by X-ray diffraction) 
could also be obtained from the linear benzimidazole 1k in a 
cascade process involving tandem [3+2]/[5+2] oxidative 
annulations17 with 2a (Scheme 3). 
Scheme 3. Rh(III)-catalyzed [3+2] and tandem [3+2]/[5+2] 












MeOH, 90 ºC, 24 h
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iPrOH, 60 ºC, 24 h
51%
2.5 mol % [RhCp*Cl2]2
200 mol % AgOAc
(1.1 eq)
 
At the outset, the cyclic arylguanidine substrates were selected to 
favor the crucial reductive elimination step over the β-elimination 
found for the eight-membered rhodacycle intermediates derived 
from the linear arylguanidines.8 We believe that the presence of the 
NH in the benzimidazole group would trigger the required tautom-
erism between the nitrogen atoms (L to X-type ligand) to facilitate 
the reductive elimination step. In fact, the 2-(indolin-1-yl)-1-
methyl-1H-benzo[d]imidazole 1j failed to react under optimized 
conditions with total recovery of the starting material. 
In an effort to gain an insight into the selectivity of the reaction 
between guanidines 1b (partially cyclic) and 1c (fully cyclic) with 
alkyne 2a to form [5+2] cycloadducts, i.e., benzodiazepines 5, or 
[5+1] cycloadducts, i.e., quinazolines 4, DFT calculations18 were 
performed starting with the key eight-membered rhodacycles I19 
which lie 14.1 (1b, blue line) and 9.9 (1c, red line) Kcal mol-1 
below the free energy of the corresponding starting materials (Fig-
ure 3). To our surprise, calculations showed that the formation of 
[5+2] cycloadducts, i.e., benzodiazepines 5, occurs by an initial 
decoordination of the imidazole moiety from the metal center to 
complex II, followed by a nucleophilic attack of the iminic nitrogen 
to the Csp2-Rh bond to afford protonated Rh(I)-coordinated ben-
zodiazepines III (∆Gǂ = 20.9 and 11.5 Kcal mol-1, ∆Gº = 6.6 and -
0.1 Kcal mol-1) rather than the expected direct reductive elimina-
tion from I (∆Gǂ = 29.5 and 26.4 Kcal mol-1, ∆Gº = 12.2 and 10.2 
Kcal mol-1).20 Exergonic deprotonation and reoxidation of the 
Rh(I) to Rh(III) with AgOAc would give the final benzodiazepines 
5ba and 5ca (∆Gº = -21.5 and -16.2 Kcal mol-1) for the overall 
transformations. On the other hand, formation of [5+1] cycload-
ducts,21 i.e., quinazolines 4, starts with coordination of acetate to 
the eight-membered cationic rhodacycles I to give neutral com-
plexes IV (∆Gº = 4.9 and 11.5 Kcal mol-1), which after acetate-
assisted β-hydride elimination afford allene intermediates V (∆Gǂ = 
11.1 and 3.9 Kcal mol-1, ∆Gº = 7.2 and 1.4 Kcal mol-1). Protonation 
of V by the acetic acid ligand affords the cationic π-allyl Rh (III) 
species VI after acetate release (∆Gǂ = 7.6 and 7.8, ∆Gº = -15.4 and 
-15.6 Kcal mol-1) where Rh(III) is stabilized by an agostic interac-
tion involving a Csp3-H bond of the ethyl substituent. Finally, nu-
cleophilic attack of the iminic nitrogen to the π-allyl moiety (∆Gǂ = 
21.3 and 21.1 Kcal mol-1) followed by exergonic deprotonation and 
reoxidation of the Rh(I) to Rh(III) by AgOAc affords the 
quinazolines 4ba and 4ca (∆Gº = -24.9 and -18.8 Kcal mol-1) for 
the overall processes. 
These calculations described above show the preference for the 
[5+2] over the [5+1] cycloaddition pathway for the fully cyclic 
guanidine 1c to benzodiazepine 5ca (∆∆Gǂ is 9.2 Kcal mol-1), while 
the opposite is observed from the partially cyclic guanidine 1b to 
quinazoline 4ba (∆∆Gǂ is 1.2 Kcal mol-1). These findings are in 
complete agreement with the experimental results found. We be-
lieve that the rigidity/planarity of the indolyl moiety in 1c (as 
compared to the linear 1b) enables the formation of complex II 
with an appropriate spatial disposition between the reactive centers 
(0.54 Å closer for fully cyclic than partially cyclic II due to the 
planarity imposed by the indolyl ring, 15.4º against 42.4º) that are 
prone to undergo the formation of the seven-membered heterocy-








































































































Figure 3. Free energy profile for the formation either of benzodiazepines 5ba and 5ca or quinazolines 4ba and 4ca21 from eight-membered rhodacy-
cles I. Energies are relative to catalytic active species Cp*Rh(OAc)2 combined with those of the relevant substrates. The phenyl ring of the benzimid-
azole moiety is omitted for clarity. 
 
Figure 4. Calculated geometries for intermediates II in guanidine 
1b (partially cyclic) and 1c (fully cyclic). 
Redox reactions of indoline-1,3-benzodiazepines 5 were per-
formed to get a straightforward access to N-doped aromatic scaf-
folds containing [4n+2]πe- with potential electroluminescent 
properties.22 Treatment of 5cd with MnO2 at 80 °C promotes the 
oxidation of the indoline moiety to give the indole-1,3-
benzodiazepine 6cd in excellent yield (Scheme 4).23 Careful hy-
drogenation of 5cd in MeOH(H2 4atm, 60ºC) affected only to the 
enamine unit to give the dihydro-1,3-benzodiazepine 7cd in fairly 
good yield. 



























In summary, we have successfully developed a new and efficient 
rhodium-catalyzed [5+2] oxidative cycloaddition between fully 
cyclic arylguanidines and alkynes to give 1,3-benzodiazepines. The 
use of O2 as the sole oxidant in place of commonly used metal 
oxidants like AgOAc clearly improves the efficiency of the oxidative 
annulation process. The reaction tolerates functional groups in 
both the guanidine and alkyne partners and provides an easy access 
to relevant pentacyclic guanidine derivatives. In addition, an 
indolo-benzazepine skeleton is smoothly assembled by a 
remarkable cascade process involving [3+2]/[5+2] oxidative 
annulations of linear benzimidazole 1k with alkyne 2a. A striking 
mechanistic rationale for the [5+2] oxidative annulation is pro-
posed based on DFT calculations. Redox reactions of the indoline-
benzodiazepines have been successfully achieved. Further applica-
tions of this novel oxidative process are currently being explored in 
our laboratory. 
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